2023
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial.
Lansky A, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson T, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Brugaletta S, Naber C, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Wijns W. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial. EuroIntervention 2023, 19: e844-e855. PMID: 37860860, PMCID: PMC10687649, DOI: 10.4244/eij-d-23-00409.Peer-Reviewed Original ResearchConceptsTarget lesion failureDP-EES groupPercutaneous coronary interventionBP-SES groupBP-SESPrimary endpointDP-EESRate of TLFBiodegradable polymer sirolimus-eluting stentsST-elevation myocardial infarction (STEMI) presentationMyocardial infarction presentationSirolimus-eluting stentsFive-year resultsLong-term safetyAbluminal grooveLesion failureSecondary endpointsComers populationCoronary interventionMyocardial ischaemiaStent implantationClinical trialsTargeted therapyLandmark analysisStudy outcomes
2021
Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials
Hussain Y, Gaston S, Kluger J, Shah T, Yang Y, Tirziu D, Lansky A. Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials. Catheterization And Cardiovascular Interventions 2021, 99: 563-574. PMID: 34236755, DOI: 10.1002/ccd.29866.Peer-Reviewed Original ResearchConceptsSecond generation drug eluting stentsTarget lesion failureDrug eluting stentsLong-term outcomesEluting stentsTerm outcomesRisk ratioIschemia-driven target vessel revascularizationTarget vessel myocardial infarctionLong-term clinical outcomesProbable stent thrombosisTarget vessel revascularizationTerm clinical outcomesVessel myocardial infarctionPercutaneous coronary interventionCoronary artery diseaseConfidence intervalsFirst generation drug eluting stentsRandom-effects modelLesion failureVessel revascularizationCoronary interventionSecondary outcomesArtery diseaseCardiac deathAbluminal groove-filled biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent: three-year results of the TARGET All Comers trial.
Saito Y, Kelbæk H, Xu B, Hussain Y, Anderson R, Schächinger V, Zheng M, Wijns W, Baumbach A, Lansky AJ. Abluminal groove-filled biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent: three-year results of the TARGET All Comers trial. EuroIntervention 2021, 17: e332-e334. PMID: 32482617, PMCID: PMC9724996, DOI: 10.4244/eij-d-20-00344.Peer-Reviewed Original ResearchNovel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease
Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB, Investigators O. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease. Circulation 2021, 143: 2143-2154. PMID: 33820424, DOI: 10.1161/circulationaha.120.052482.Peer-Reviewed Original ResearchConceptsDurable polymer everolimus-eluting stentsDrug-eluting stentsTarget lesion revascularizationAntiproliferative drug deliveryChronic coronary syndromeVessel myocardial infarctionLesion revascularizationCoronary syndromeLesion failureMyocardial infarctionDrug-Eluting Stent ImplantationTarget vessel myocardial infarctionLong-term clinical outcomesDP-EES groupPrimary end pointTarget lesion failureSmooth muscle cell proliferationPercutaneous coronary interventionSingle-blind trialCoronary artery diseaseEverolimus-eluting stentsMuscle cell proliferationLong-term inflammatory responseDrug eluting stentsCardiovascular deathRefining drug-eluting stent technologies: from engineering to basic science
Lansky A, Chun H, Pietras C, Hussain Y. Refining drug-eluting stent technologies: from engineering to basic science. European Heart Journal 2021, 42: 1770-1772. PMID: 33624813, DOI: 10.1093/eurheartj/ehab091.Peer-Reviewed Original ResearchDifferential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy
Saito Y, Wijns W, Baumbach A, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Differential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy. Catheterization And Cardiovascular Interventions 2021, 99: 357-365. PMID: 33502809, DOI: 10.1002/ccd.29468.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyTarget lesion failureDrug-eluting stentsTarget vessel myocardial infarctionBiodegradable polymer drug-eluting stentsChronic coronary syndromeAcute coronary syndromeDAPT discontinuationVessel myocardial infarctionAntiplatelet therapyCoronary syndromeMyocardial infarctionDurable polymer drug-eluting stentsIschemia-driven target lesion revascularizationIschemic coronary artery diseaseTarget lesion revascularizationIschemia-driven revascularizationPercutaneous coronary interventionCoronary artery diseaseIschemic coronary diseaseComer studyLesion revascularizationDAPT durationLesion failurePrimary endpoint
2020
Management of myocardial revascularisation failure: an expert consensus document of the EAPCI.
Stefanini GG, Alfonso F, Barbato E, Byrne RA, Capodanno D, Colleran R, Escaned J, Giacoppo D, Kunadian V, Lansky A, Mehilli J, Neumann FJ, Regazzoli D, Sanz-Sanchez J, Wijns W, Baumbach A. Management of myocardial revascularisation failure: an expert consensus document of the EAPCI. EuroIntervention 2020, 16: e875-e890. PMID: 32597391, DOI: 10.4244/eij-d-20-00487.Peer-Reviewed Original ResearchMeSH KeywordsConsensusCoronary Artery DiseaseDrug-Eluting StentsHumansMyocardial RevascularizationQuality of LifeTreatment OutcomeConceptsConsensus documentLong-term clinical outcomesRepeat revascularisation proceduresCoronary artery bypassPercutaneous coronary interventionCoronary artery diseasePercutaneous Cardiovascular InterventionsNative coronary segmentsDrug-eluting stentsExpert consensus documentArterial bypass graftsSignificant economic burdenPatient-oriented approachArtery bypassMyocardial revascularisationRepeat revascularisationRevascularisation proceduresCoronary interventionArtery diseaseBypass graftClinical outcomesRevascularisation techniquesPatients' qualityClinical managementCoronary segmentsThe Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent.
Saito Y, Grubman D, Cristea E, Lansky A. The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. Cardiology In Review 2020, 28: 208-212. PMID: 32032131, DOI: 10.1097/crd.0000000000000298.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsDrug-Eluting StentsHumansInflammationPercutaneous Coronary InterventionSirolimusTreatment OutcomeConceptsAbluminal grooveFIREHAWK stentBiodegradable Polymer Sirolimus-Eluting StentLate adverse eventsPercutaneous coronary interventionCurrent clinical evidenceSirolimus-Eluting StentsDrug-eluting stent technologyAdverse eventsCoronary interventionClinical outcomesChronic inflammationClinical evidenceHypersensitivity reactionsRecent trialsDrug concentrationsStent technologyStentsInflammationFIREHAWKReviewSirolimusDefining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.
Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky AJ, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention 2020, 15: 1190-1198. PMID: 31475907, DOI: 10.4244/eij-d-19-00552.Peer-Reviewed Original ResearchMeSH KeywordsCoronary Artery DiseaseDrug-Eluting StentsHumansPercutaneous Coronary InterventionReproducibility of ResultsTreatment OutcomeConceptsDevice success rateDrug-eluting stentsPercutaneous coronary intervention trialsCoronary intervention trialsDevice successIntervention trialsClinical trialsSuccess rateSymptomatic coronary artery diseasePercutaneous coronary interventionAdverse clinical eventsCoronary artery diseasePercutaneous Cardiovascular InterventionsDifferent trialsRevascularisation proceduresCoronary interventionAngiographic outcomesArtery diseaseClinical eventsComparative trialsEndpoint definitionsDrug AdministrationCardiovascular interventionsPerformance endpointEuropean Association
2019
Validation of the all-comers design: Results of the TARGET-AC substudy
G Toth G, Lansky A, Baumbach A, Kelbæk H, van Royen N, Holmvang L, Janssens L, Brugaletta S, Barbato E, Maillard L, Kiemeneij F, Naber CK, Pucher F, Laursen PN, Ameloot K, Robles C, Milkas A, Sevilla J, Jensen C, Wijns W. Validation of the all-comers design: Results of the TARGET-AC substudy. American Heart Journal 2019, 221: 148-154. PMID: 31924299, DOI: 10.1016/j.ahj.2019.10.019.Peer-Reviewed Original ResearchConceptsComers designRisk factorsNon-ST elevation acute coronary syndromeElevation acute coronary syndromeNER groupReal-world clinical practiceGroup more patientsInternational multicentre registrySignificant valvular diseaseST-elevation infarctionAcute coronary syndromeChronic total occlusionWorld clinical practiceLow inclusion rateMulticentre registryThrombotic stenosisCoronary syndromePrimary PCIStable anginaAngiographic parametersComers populationPatient demographicsStable patientsStudy nursesMore patientsClinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent
Saito Y, Baumbach A, Wijns W, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent. Catheterization And Cardiovascular Interventions 2019, 96: 1023-1028. PMID: 31769161, DOI: 10.1002/ccd.28609.Peer-Reviewed Original ResearchConceptsHigh-risk patientsClinical outcomesComer studyI trialDurable polymer everolimus-eluting stentsTarget vessel myocardial infarctionSirolimus-eluting coronary stentYear clinical outcomesTarget lesion failureVessel myocardial infarctionLow-risk patientsWorse clinical outcomesEverolimus-eluting stentsHigh-risk groupLow-risk groupStrict eligibility criteriaFIREHAWK stentLesion failurePrimary endpointRandomized trialsMyocardial infarctionRisk groupsInclusion criteriaComplex lesionsXIENCE stentPaclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis
Lansky A, Grubman D, Scheller B. Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis. European Heart Journal 2019, 41: 3729-3731. PMID: 31702784, DOI: 10.1093/eurheartj/ehz731.Peer-Reviewed Original Research2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W, Investigators T. 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC Cardiovascular Interventions 2019, 12: 1679-1687. PMID: 31129092, DOI: 10.1016/j.jcin.2019.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary ThrombosisDrug-Eluting StentsDual Anti-Platelet TherapyEuropeEverolimusFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureXIENCE stentXience groupLesion failurePrimary endpointClinical outcomesIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionLong-term outcomesDurable polymer everolimusBiodegradable Polymer SirolimusAbluminal grooveFIREHAWK stentLesion revascularizationCardiac deathComparable safetyStent thrombosisMyocardial infarctionClinical trialsEfficacy profileNoninferiority trialLandmark analysis
2018
Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers.
Baumbach A, Lansky AJ, Onuma Y, Asano T, Johnson T, Anderson R, Kiemeneij F, Zheng M, Van Royen N, Slagboom T, Vlachojannis G, Xu B, Serruys P, Wijns W. Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers. EuroIntervention 2018, 14: 1121-1128. PMID: 29901441, DOI: 10.4244/eij-d-18-00226.Peer-Reviewed Original ResearchConceptsOptical coherence tomography substudyPrimary endpointProspective multicentreStrut coveragePost-market trialDP-DESNeointimal thicknessDurable polymer drug-eluting stentsComers patient populationComplete strut coverageLate DES thrombosisSirolimus-eluting stentsStent strut coverageMean neointimal thicknessCoronary stent systemDrug-eluting stentsOCT substudyConsecutive patientsDES thrombosisPersistent inflammationPatient populationBP-DESNeointimal coverageEndothelial healingAtherosclerotic lesionsTargeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A, Investigators T. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. The Lancet 2018, 392: 1117-1126. PMID: 30190206, DOI: 10.1016/s0140-6736(18)31649-0.Peer-Reviewed Original ResearchConceptsLate lumen lossStent late lumen lossTarget lesion failureCoronary artery diseaseNon-inferiority trialXience groupPrimary endpointLesion failureLumen lossAbluminal grooveAngiographic substudyComers populationArtery diseaseMyocardial ischaemiaMyocardial infarctionIschaemia-driven target lesion revascularisationAsymptomatic coronary artery diseaseTarget vessel myocardial infarctionIschemic coronary artery diseaseST-elevation myocardial infarctionRandom block allocationTarget lesion revascularisationStent thrombosis ratesVessel myocardial infarctionElevation myocardial infarction
2017
Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions
Kitahara H, Okada K, Kimura T, Yock PG, Lansky AJ, Popma JJ, Yeung AC, Fitzgerald PJ, Honda Y. Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions. Circulation Cardiovascular Interventions 2017, 10: e004795. PMID: 28951394, DOI: 10.1161/circinterventions.116.004795.Peer-Reviewed Original ResearchMeSH KeywordsCoronary AngiographyCoronary Artery DiseaseDrug-Eluting StentsHumansTreatment OutcomeUltrasonography, InterventionalConceptsDrug-eluting stent implantationReference vessel diameterLong-term outcomesDe novo coronary lesionsNovo coronary lesionsStent implantationDrug-eluting stentsIncomplete stent appositionClinical outcomesCoronary lesionsStent thrombosisStent oversizingStent appositionAngiographic reference vessel diameterSmaller reference vessel diameterGreater stent expansionLesion revascularization rateTarget lesion revascularizationGreater adverse eventsSerial coronary angiographyArterial wall injuryStent size selectionLesion revascularizationRevascularization ratesAdverse events
2016
Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials
Bouras G, Jhamnani S, Ng VG, Haimi I, Mao V, Deible R, Cao S, Sudhir K, Lansky AJ. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization And Cardiovascular Interventions 2016, 89: 984-991. PMID: 27545721, DOI: 10.1002/ccd.26711.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsLong coronary lesionsTarget lesion failurePercutaneous coronary interventionAcademic Research ConsortiumMean lesion lengthCoronary lesionsXIENCE VCoronary interventionStent thrombosisLesion lengthRate of TLFControl groupSecond generation drug eluting stentsLong lesion groupAdverse cardiac eventsProbable stent thrombosisPrimary outcome measureCoronary stent systemDrug eluting stentsLesion failureCardiac eventsPooled analysisWorse outcomesLesion groupWhat the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis
Lansky AJ, Ng VG. What the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis. Circulation Cardiovascular Interventions 2016, 9: e003861. PMID: 27162219, DOI: 10.1161/circinterventions.116.003861.Peer-Reviewed Original Research
2015
Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies)
Lansky AJ, Kastrati A, Edelman ER, Parise H, Ng VG, Ormiston J, Wijns W, Byrne RA. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). The American Journal Of Cardiology 2015, 117: 532-538. PMID: 26762729, PMCID: PMC5975354, DOI: 10.1016/j.amjcard.2015.11.044.Peer-Reviewed Original ResearchEffect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)
Prasad A, Gersh BJ, Mehran R, Brodie BR, Brener SJ, Dizon JM, Lansky AJ, Witzenbichler B, Kornowski R, Guagliumi G, Dudek D, Stone GW. Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). JACC Cardiovascular Interventions 2015, 8: 1966-1974. PMID: 26738667, DOI: 10.1016/j.jcin.2015.08.031.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCoronary CirculationDrug-Eluting StentsFemaleHumansMaleMetalsMicrocirculationMiddle AgedMyocardial InfarctionMyocardial Perfusion ImagingPercutaneous Coronary InterventionProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsStentsTime FactorsTime-to-TreatmentTreatment OutcomeConceptsPrimary percutaneous coronary interventionMyocardial blush gradePrimary PCIHORIZONS-AMI trialMBG 0/1Balloon timeIndependent predictorsAnterior infarctionMyocardial perfusionST-segment elevation myocardial infarction (STEMI) patientsST-segment elevation myocardial infarctionHigher clinical risk profileElevation myocardial infarction patientsMyocardial Infarction (TIMI) risk scoreClinical risk profileMechanical reperfusion therapyReference vessel diameterElevation myocardial infarctionPercutaneous coronary interventionST-segment elevationEpicardial blood flowMinimum lumen diameterMyocardial infarction patientsMicrovascular reperfusionBlush grade